Inflammatory Neuropathy Consortium Base

Inflammatory Neuropathy Consortium Base - INCbase

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49801

Enrollment

200

Registered

2020-04-01

Start date

2021-04-26

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammatory demyelinating polyneuropathie CIDP

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: clinical suspicion of the diagnosis CIDP

Exclusion criteria

Exclusion criteria: The presence of any condition, that at the discretion of the study investigator or study participant, impairs the participants ability to provide accurate study information in a timely and reliable manner

Design outcomes

Primary

Measure	Time frame
Prediction model to predict treatment response	—

Secondary

Measure	Time frame
1) to discover clinical, electrophysiological and biological biomarkers for diagnosis, disease activity and prognosis, 2) to describe variation in clinical and electrophysiological characteristics of CIDP to define the spectrum and boundaries of CIDP, 3) to describe short and long-term outcomes at impairment, disability and quality of life levels of (subgroups of) CIDP patients, 4) to discover clinical, electrophysiological and biological determinants of treatment response and long-term outcomes, 5) to describe physician and patient perspectives on and satisfaction with different treatments that may be used for CIDP, including plasma-exchange and subcutaneous immunoglobulin and 6) to deepen knowledge on CIDP pathophysiology, including investigating immunological pathways underlying CIDP.	—

Measure

Time frame

1) to discover clinical, electrophysiological and biological biomarkers for diagnosis, disease activity and prognosis, 2) to describe variation in clinical and electrophysiological characteristics of CIDP to define the spectrum and boundaries of CIDP, 3) to describe short and long-term outcomes at impairment, disability and quality of life levels of (subgroups of) CIDP patients, 4) to discover clinical, electrophysiological and biological determinants of treatment response and long-term outcomes, 5) to describe physician and patient perspectives on and satisfaction with different treatments that may be used for CIDP, including plasma-exchange and subcutaneous immunoglobulin and 6) to deepen knowledge on CIDP pathophysiology, including investigating immunological pathways underlying CIDP.

—

Countries

Netherlands

Outcome results